Advertisement
AddendumCardiology Free access | 10.1172/JCI15598A1
Find articles by Heximer, S. in: JCI | PubMed | Google Scholar
Find articles by Knutsen, R. in: JCI | PubMed | Google Scholar
Find articles by Sun, X. in: JCI | PubMed | Google Scholar
Find articles by Kaltenbronn, K. in: JCI | PubMed | Google Scholar
Find articles by Rhee, M. in: JCI | PubMed | Google Scholar
Find articles by Peng, N. in: JCI | PubMed | Google Scholar
Find articles by Oliveira-dos-Santos, A. in: JCI | PubMed | Google Scholar
Find articles by Penninger, J. in: JCI | PubMed | Google Scholar
Find articles by Muslin, A. in: JCI | PubMed | Google Scholar
Find articles by Steinberg, T. in: JCI | PubMed | Google Scholar
Find articles by Wyss, J. in: JCI | PubMed | Google Scholar
Find articles by Mecham, R. in: JCI | PubMed | Google Scholar
Find articles by Blumer, K. in: JCI | PubMed | Google Scholar
Published April 15, 2003 - More info
Original citation: J. Clin. Invest.111:445–452 (2003). doi:10.1172/JCI15598.
The authors wish to add the following information.
Table 1: The doses of antagonists used to treat wild-type and RGS2-knockout mice were hexamethonium at 5 mg/kg i.v., prazosin at 200 μg/kg i.v., and candesartan at 100 μg/kg i.v. Effective ganglionic blockade by hexamethonium was established as described previously, whereas blockade by prazosin or candesartan was demonstrated by the inability of a subsequent infusion of phenylephrine (10 μg/kg i.v.) or angiotensin II (1 μg/kg i.v.) to increase blood pressure of wild-type or RGS2-knockout mice.
Figure 3: Blood pressure responses were determined using anesthetized mice as described in Methods. In Figure 3a, the doses of vasoconstrictors used to treat wild-type and RGS2-knockout mice were 1 μg/kg i.v. for angiotensin II and 10 μg/kg i.v. for phenylephrine. These doses were determined empirically, as were those that elicited a near-maximal (>75%) increase in blood pressure (determined by dose-response experiments such as those shown in Figure 4a for phenylephrine). In Figure 3b, candesartan (100 μg/kg i.v.) was infused into wild-type and RGS2-knockout mice over a period of 10 seconds, after which blood pressure was recorded continuously over the time period indicated. In Figure 3c, the same dose of angiotensin II (1 μg/kg iv) was used to treat wild-type and RGS2-knockout mice in order to increase systolic blood pressure to similar absolute levels (160-170 mmHg) prior to antagonist infusion (candesartan, 100 μg/kg i.v.). This approach was established by the results shown in Figure 3a, in which MAP of wild-type mice increased from a resting value (prior to agonist infusion) of ∼85 mmHg to a value of ∼135 mmHg after angiotensin II infusion, and the MAP of RGS2-knockout mice increased from a resting value of ∼135 mmHg to ∼140 mmHg by the same treatment. After a maximal effect of angiotensin II on blood pressure was achieved (∼1 minute), candesartan (100 μg/kg i.v.) was infused over 10 seconds, and decreases in blood pressure were recorded continuously over the time period indicated.